Dosimetric Comparison of VMAT Alone and VMAT with HDR Brachytherapy Boost Using Clinical and Biological Dose Models in Localized Prostate Cancer
Authors:
- Manuel GuhlichManuel Guhlich
- Olga KnausOKOlga Knaus
- Arne StraussASArne Strauss
- Laura Anna FischerLFLaura Anna Fischer
- Jann FischerJFJann Fischer
- Stephanie BendrichSBStephanie Bendrich
- Sandra DonathSDSandra Donath
- Leif Hendrik DrögeLDLeif Hendrik Dröge
- Martin LeuMLMartin Leu
- Stefan RiekenSRStefan Rieken
- Annemarie UhligAUAnnemarie Uhlig
- Markus Anton SchirmerMarkus Anton Schirmer
Open Access
- 19 June 2025
- journal article
- research article
- Published by MDPI AG in Current Oncology
- Vol. 32 (6) , 360
Abstract
Background: Combining external beam radiotherapy (EBRT) with high-dose-rate (HDR) brachytherapy (BT) enables biologically effective dose escalation in prostate cancer. However, comparative evaluation of such regimens using radiobiological modeling remains limited. Methods: Dose regimens based on clinical practice were analyzed using α/β values of 1.5 and 3 Gy for the prostate. Ten patients with available planning CT, pelvic MRI, and ultrasound-guided BT plans were retrospectively evaluated. Physical and biological dose distributions were recalculated for various EBRT and HDR-BT combinations. Biological effective dose (BED) values were determined for the prostate and organs at risk (OARs: anterior rectal wall, bladder base, urethra). Regimens yielding the highest ΔBED between prostate and OARs were considered most favorable. Results: All regimens met clinical dose constraints. The most favorable ΔBED profiles for bladder and rectum were observed with HDR-BT regimens (2 × 15 Gy) combined with either 23 × 2 Gy or 15 × 2.5 Gy EBRT, independent of the assumed α/β value. EBRT-only regimens achieved superior urethral sparing, while higher HDR doses led to increased urethral exposure. Conclusions: This study underscores the value of radiobiological modeling in differentiating and optimizing prostate cancer radiotherapy strategies. While the trade-offs between dose escalation and OAR sparing are clinically known, our biologically driven analysis provides a more quantitative foundation for selecting and tailoring combined EBRT/HDR-BT regimens in practice.Keywords
This publication has 55 references indexed in Scilit:
- Long-term outcomes of high-dose-rate brachytherapy and external beam radiotherapy without hormone therapy for high-risk localized prostate cancerJapanese Journal of Radiology, 2024
- Real-world dosimetric comparison between CyberKnife SBRT and HDR brachytherapy for the treatment of prostate cancerBrachytherapy, 2021
- Association of the Placement of a Perirectal Hydrogel Spacer With the Clinical Outcomes of Men Receiving Radiotherapy for Prostate CancerJAMA Network Open, 2020
- A phase IB clinical trial of 15 Gy HDR brachytherapy followed by hypofractionated/SBRT in the management of intermediate-risk prostate cancerBrachytherapy, 2020
- Evaluation of the urethral α/β ratio and tissue repair half-time for iodine-125 prostate brachytherapy with or without supplemental external beam radiotherapyBrachytherapy, 2020
- Effect of Standard vs Dose-Escalated Radiation Therapy for Patients With Intermediate-Risk Prostate CancerJAMA Oncology, 2018
- Dose-Escalated Irradiation and Overall Survival in Men With Nonmetastatic Prostate CancerJAMA Oncology, 2015
- Comparison of dose-escalated, image-guided radiotherapy vs. dose-escalated, high-dose-rate brachytherapy boost in a modern cohort of intermediate-risk prostate cancer patientsBrachytherapy, 2014
- The emerging role of high-dose-rate brachytherapy for prostate cancerClinical Oncology, 2005
- Local staging of prostate carcinoma with endorectal coil MRI: correlation with whole-mount radical prostatectomy specimensEuropean Radiology, 1996